OBJECTIVES: Postmenopausal (PM) women taking hormone therapies (HT) can experience side effects (breast pain/vaginal bleeding), impacting quality of life and increasing likelihood of discontinuation. The sensitivity of the EQ-5D-5L in PM women on HT is unknown. The purpose of this research was to develop a crosswalk between scores from the Menopause-Specific Quality of Life questionnaire (MENQOL) and EQ-5D-5L and assess sensitivity. METHODS: The MENQOL and EQ-5D-5L were co-administered to 351 PM women in an observational, non-interventional study. Total MENQOL scores were mapped onto EQ-5D-5L utilities using repeated measures regression (RMM) with MENQOL scores as a continuous predictor. The predictability, goodness-of-fit and signs of the estimated coefficients were assessed in sensitivity analyses using averaged scores over time in an Ordinary Least-Square regression (OLS)  and using MENQOL scores as a categorical predictor in a RMM. RESULTS: The sample consisted of n=276 PM women (n=202 on HT, side effects; n=74 on HT, no side effects; n=75 not on HT). Mean age was 53.7 (SD 6.6) years. The main model (employing MENQOL total score as a continuous variable), showed sizable and significant correlation with the EQ-5D-5L (-0.589; P<.001) and a relationship of EQ-5D-5L=0.992-0.042×MENQOL. EQ-5D-5L mean scores (on HT, side effects= 0.854 [SD 0.12]; on HT, no side effects=0.927 [SD 0.11]; not on HT=0.836 [SD 0.11]) were comparable to those estimated in the main model (on HT, side effects=0.865 [SD 0.07]; on HT, no side effects=0.909 [SD 0.05]; not on HT=0.833 [SD 0.06]) on a scale of -0.11 to 1. Linearity assumptions were supported by RMM with MENQOL scores as a categorical predictor. Goodness-of-fit was moderate (R=0.347; Root mean squared error=0.093) using OLS with averaged scores over time. CONCLUSIONS: The crosswalk performed in this study supports conversion of MENQOL scores to EQ-5D-5L derived health utilities and can be used for group-level analyses of utilities in PM women.